arrow
F

Filippo Gustavo Dall'Olio

gustave roussy
H指数:22
被引数:2,217

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy of Alectinib for ALK-positive NSCLC According to Tumor Burden and Body Mass Index: a Pooled Analysis of the Randomized Phase III Trials ALEX and J-ALEX

根据肿瘤负荷和体重指数评估阿来替尼对ALK阳性NSCLC的疗效:ALEX和J-ALEX随机III期试验的合并分析

2026-06-050
OAAI
Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients

肛门鳞状细胞癌的全面分子图谱:1844例患者的组织活检和液体活检分析

2025-11-240
OAAI
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50%

PD-L1 ≥50%的晚期非小细胞肺癌患者,在初次免疫治疗原发性耐药后,采用疾病进展后联合铂类为基础的化疗的免疫治疗。

2025-11-170
OAAI
Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancer

基线CT测量的肿瘤负荷和液体活检作为预测转移性实体癌患者生存的生物标志物

2025-06-080
PRE
Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer
2024-11-280
OAAI
Feasibility and clinical utility of blood based NGS in head and neck carcinomas: A single center experience from precision medicine program
2024-03-220
PRE
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients

癌症患者中TP53和DNA损伤基因的液体活检突变的基因组景观

2024-02-263
OA
Clinical features of progression and outcomes with subsequent therapies in patients treated with RET-inhibitors
2023-12-010
PRE
Clinical utility of liquid biopsy for molecular characterization and resistance detection in patients with advanced NSCLC and ALK, ROS1 or RET fusions
2023-04-040
PRE